Essential Premium

Hedgies Eye Three Biopharma IPOs

A number of prominent hedge funds hope to duplicate the success of the most recent biopharma offerings.

Consultants & Institutional Investors Roundtable

October 7-8, 2026 | Four Seasons Hotel

Skye Global’s Amazon Problem

Jamie Sterne’s once high-flying hedge fund has recently been lagging the broad market.

Sponsored

Stagflation: Risks and Opportunities in Global Equities

Seligman’s AI Winners ‘Carry the Fund’

Semiconductor, memory, networking, and power bets fueled outsized gains, more than offsetting continued weakness across software, internet, and payments stocks.

Related Content

The Rich List: Institutional Investor’s 25th Annual Ranking of the Highest-Earning Hedge Fund Managers

Stephen Taub

Coatue, Tiger Global, and Rosie

Stephen Taub

Marc Rubinstein on the Hidden Fault Lines in Modern Finance

Michelle Celarier

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram